Key result
Post-TAVI antithrombotic therapy lacks high-grade evidence, requiring individualized treatment based on patient characteristics.
Why the study?
The optimal antithrombotic regimen following TAVI remains uncertain, as antithrombotic therapy to prevent thrombotic complications exposes patients to bleeding risks and current clinical guidelines rely mostly on low-grade evidence.
What is the optimal antithrombotic pharmacotherapy regimen following transcatheter aortic valve implantation (TAVI)?
What is the optimal antithrombotic pharmacotherapy regimen following transcatheter aortic valve implantation (TAVI)?
This review highlights the uncertainty in optimal antithrombotic therapy post-TAVI and emphasizes individualized treatment pending further RCT data.
No takes yet. Share an insight, caveat, or question.
Individualized antithrombotic therapy remains preferred post-TAVI; leaves open optimal regimen until RCTs report.
Greco et al. (2019) conducted a review in Severe aortic stenosis post-TAVI. Antithrombotic pharmacotherapy was evaluated. Antithrombotic pharmacotherapy following TAVI currently lacks high-grade evidence, making individualized therapy based on patient characteristics the preferred approach while awaiting trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: